Men's Health
Profound Medical goes public in reverse merger
Profound Medical yesterday said it’s slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.
Augmenix wins FDA nod for SpaceOar prostate treatment
FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to help protect the rectum during prostate cancer radiotherapy, CEP John Pedersen told MassDevice.com today.
Uroplasty, Vision-Sciences merge as Cogentix
Uroplasty, Vision-Sciences shareholders OK merger
Bioness launches clinical trial for StimRouter in overactive bladder
Bioness last week said it’s making progress with a Canadian study of its StimRouter neuromodulation device designed to expand the number of conditions for which it can be used for treatment.